Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Teva Pharmaceutical Industries ADR (NY: TEVA )

14.05 -0.05 (-0.35%)
Official Closing Price Updated: 7:00 PM EDT, Apr 30, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 8,541,686
Open 13.99
Bid (Size) 13.89 (1)
Ask (Size) 14.20 (1)
Prev. Close 14.10
Today's Range 13.94 - 14.19
52wk Range 7.085 - 14.46
Shares Outstanding 1,110,352,397
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab)
From Teva Pharmaceutical Industries Limited
Via Business Wire
U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab)
From Alvotech
Via GlobeNewswire

Performance

YTD
+31.68%
+31.68%
1 Month
+1.01%
+1.01%
3 Month
+19.78%
+19.78%
6 Month
+63.75%
+63.75%
1 Year
+58.94%
+58.94%

More News

Read More
US Supreme Court Declines To Hear Vanda Pharmaceuticals' Case Regarding Invalidation Of Patents For Its Sleep Disorder Drug, Hetlioz
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
8 Analysts Assess Teva Pharmaceutical Indus: What You Need To Know
Via Benzinga
Update: Israeli Stocks On U.S. Exchanges Have Outpaced Nasdaq And S&P 500 Since October 7/23
Via Talk Markets
Topics Stocks
Exposures US Equities
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)
From Teva Pharmaceutical Industries Limited
Via Business Wire
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)
From Alvotech
Via GlobeNewswire
Teva’s New Real-World Evidence Presented at the 2024 AAN Annual Meeting Confirms Effectiveness and Patient Satisfaction for HD Chorea with the 4-week Titration Kit for AUSTEDO® (deutetrabenazine) Tablets
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva Confirms Efficacy and Safety of AJOVY® (fremanezumab) for the Prevention of Migraine With Results from Phase 3 Trial in China
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva to Host Conference Call to Discuss First Quarter 2024 Financial Results at 8 a.m. ET on May 8, 2024
From Teva Pharmaceutical Industries Limited
Via Business Wire
Forget Nvidia: 3 Prominent Billionaire Investors Are Selling It and Buying These 6 Value Stocks Instead
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
New Pharmacokinetic Modeling Data Presented by Teva Simulates Clinical Profiles of Schizophrenia Patients Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension at SIRS 2024
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva and mAbxience Announce Strategic Global Licensing Agreement for Oncology Biosimilar Candidate
From Teva Pharmaceutical Industries Limited
Via Business Wire
3 No-Brainer Stocks to Buy With $600 Right Now
Via The Motley Fool
Clinical Collaboration Agreement between Teva and Launch Therapeutics to Accelerate Development of Dual-Action Asthma Rescue Inhaler (ICS-SABA/TEV-’248) Respiratory Program; Teva and Abingworth Enter Strategic Development Funding Agreement
From Teva Pharmaceutical Industries Limited
Via Business Wire
Cramer Isn't 'Knocking' This Pharma Firm Anymore: 'As A Matter Of Fact, I'm Going In'
Via Benzinga
Senator Bernie Sanders Applauds GSK's Move To Cap Inhaler Costs At $35 Per Month
Via Benzinga
The Generic Drugs Antitrust Case
Via Talk Markets
Week In Review: Mabwell Sells Ex-China Rights To Rare Disease Therapy In $412 Million Deal
Via Talk Markets
Drug Maker Organon Stock Scores Relative Strength Upgrade
Via Investor's Business Daily
Why Freshpet Shares Are Trading Higher By Around 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Ethereum Price Predictions: Where Will the ETH Crypto Go After Retaking $3,000?
Via InvestorPlace
Jefferies Just Raised Its Price Target on Salesforce (CRM) Stock
Via InvestorPlace
TEVA Stock Pops 4% as Teva Receives FDA Approval
Via InvestorPlace
Exposures Product Safety
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.